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Invasive versus non-invasive management of older 
patients with non-ST elevation myocardial infarction 
(SENIOR-NSTEMI): a cohort study based on routine clinical 
data
Amit Kaura, Jonathan A C Sterne, Adam Trickey, Sam Abbott, Abdulrahim Mulla, Benjamin Glampson, Vasileios Panoulas, Jim Davies, 
Kerrie Woods, Joe Omigie, Anoop D Shah, Keith M Channon, Jonathan N Weber, Mark R Thursz, Paul Elliott, Harry Hemingway, Bryan Williams, 
Folkert W Asselbergs, Michael O’Sullivan, Graham M Lord, Narbeh Melikian, Thomas Johnson, Darrel P Francis, Ajay M Shah, Divaka Perera, 
Rajesh Kharbanda, Riyaz S Patel, Jamil Mayet
Summary
Background Previous trials suggest lower long-term risk of mortality after invasive rather than non-invasive 
management of patients with non-ST elevation myocardial infarction (NSTEMI), but the trials excluded very elderly 
patients. We aimed to estimate the effect of invasive versus non-invasive management within 3 days of peak troponin 
concentration on the survival of patients aged 80 years or older with NSTEMI.
Methods Routine clinical data for this study were obtained from five collaborating hospitals hosting NIHR 
Biomedical Research Centres in the UK (all tertiary centres with emergency departments). Eligible patients 
were 80 years old or older when they underwent troponin measurements and were diagnosed with NSTEMI 
between 2010 (2008 for University College Hospital) and 2017. Propensity scores (patients’ estimated probability of 
receiving invasive management) based on pretreatment variables were derived using logistic regression; patients 
with high probabilities of non-invasive or invasive management were excluded. Patients who died within 3 days of 
peak troponin concentration without receiving invasive management were assigned to the invasive or non-invasive 
management groups based on their propensity scores, to mitigate immortal time bias. We estimated mortality 
hazard ratios comparing invasive with non-invasive management, and compared the rate of hospital admissions for 
heart failure.
Findings Of the 1976 patients with NSTEMI, 101 died within 3 days of their peak troponin concentration and 375 were 
excluded because of extreme propensity scores. The remaining 1500 patients had a median age of 86 (IQR 82–89) years 
of whom (845 [56%] received non-invasive management. During median follow-up of 3·0 (IQR 1·2–4·8) years, 
613 (41%) patients died. The adjusted cumulative 5-year mortality was 36% in the invasive management group and 
55% in the non-invasive management group (adjusted hazard ratio 0·68, 95% CI 0·55–0·84). Invasive management 
was associated with lower incidence of hospital admissions for heart failure (adjusted rate ratio compared with 
non-invasive management 0·67, 95% CI 0·48–0·93).
Interpretation The survival advantage of invasive compared with non-invasive management appears to extend to 
patients with NSTEMI who are aged 80 years or older.
Funding NIHR Imperial Biomedical Research Centre, as part of the NIHR Health Informatics Collaborative.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Most patients with a non-ST elevation myocardial infarction 
(NSTEMI) are aged 70 years or older.1 The proportion of 
the global population aged 80 years or older is projected 
to triple over the next 20 years.2 Increasing age is a key 
predictor of adverse events in patients with coronary artery 
disease: older patients presenting with an acute coronary 
syndrome are at higher risk of short-term and long-
term adverse out comes compared with younger patients.3,4 
However, the rate of invasive coronary angiography 
declines with age. Only 38% of patients with NSTEMI who 
are aged 81 years or older receive a coronary angiogram, 
compared with 78% of those aged 60 years or younger.5
Large randomised trials showed a long-term survival 
advantage for invasive management compared with 
non-invasive management of NSTEMI, but the mean 
age of participants was 66 years. Few patients in their 
80s were enrolled into these studies and the survival 
benefit cannot be assumed to translate to these patients.6 
Because of the perceived higher risks of invasive 
procedures, many physicians manage only a minority of 
older patients with NSTEMI invasively.
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Registry studies have attempted to address whether the 
benefit of invasive management extends to older patients.7–9 
In routine care, frail patients with multiple comorbidities 
are much more likely to be treated non-invasively whereas 
the fittest patients are much more likely to undergo 
invasive management. Although these studies attempted 
to control for this confounding by indication, their results 
might have been affected by immortal time bias10,11 because 
patients who died early in the course of their presentation—
before invasive therapy could be considered or arranged—
were assigned to the non-invasive group.
Questions about comparative effectiveness should 
ideally be answered using randomised trials.12 The 
SENIOR-RITA trial13 aims to determine whether an 
invasive compared with a non-invasive management 
strategy reduces time to cardiovascular death or non-fatal 
myocardial infarction in patients aged 75 years or older 
with NSTEMI. However, the final completion date is not 
expected until 2029.13
Estimates of comparative effectiveness from observa-
tional databases might be improved through specification 
of the hypothetical (target) randomised trial, the results 
of which would answer the specific clinical question of 
interest.14 We estimated the effect of invasive manage-
ment compared with non-invasive management on 
survival in patients aged 80 years or older with NSTEMI 
using multicentre routinely collected clinical data 
(SENIOR-NSTEMI study), using methods that help to 
minimise bias in analyses of observational data through 
consideration of the target trial.
Methods
Study design and participants
The National Institute for Health Research (NIHR) 
Health Informatics Collaborative was established to 
facilitate the sharing and routine reuse of clinical data 
for trans lational research.15,16 Data for this study were 
obtained from five collaborating hospitals hosting 
NIHR Biomedical Research Centres (Imperial College 
Healthcare, London; University College Hospital, 
London; Oxford University Hospitals, Oxford; King’s 
College Hospital, London; and Guys & St Thomas’ 
Research in context
Evidence before this study
Electronic searches of MEDLINE, EMBASE, and the Cochrane 
Central Register of Controlled Trials were done for articles in 
English published from inception of these databases to 
Jan 20, 2019. Studies with the following characteristics were 
identified: (1) randomised trials or observational studies, 
either restricted to populations aged 75 years or older reporting 
outcomes for this patient subgroup; (2) patients presenting 
with non-ST elevation myocardial infarction (NSTEMI); 
and (3) comparison of invasive management (coronary 
angiography or percutaneous coronary intervention or 
coronary artery bypass grafting during index admission) with 
non-invasive management during the index hospital 
admission. Only 38% of patients with NSTEMI aged 81 years or 
older receive a coronary angiogram, compared with 78% of 
those aged 60 years or younger. In routine care, frail patients 
with multiple comorbidities are less likely to be treated 
invasively. Large randomised trials have shown a long-term 
survival advantage for invasive compared with non-invasive 
management of NSTEMI, but the mean age of these 
participants was 66 years. Few patients aged 80 years or older 
were enrolled into these studies and as a result the survival 
benefit cannot be assumed to translate to older patients. 
Because the evidence to support invasive management is not 
conclusive, many physicians treat older patients with NSTEMI 
symptomatically, offering invasive management only to 
selected patients, such as those with ongoing chest pain.
The European Society of Cardiology and American Heart 
Association guidelines suggest that older patients with NSTEMI 
should be considered for invasive management with coronary 
angiography and revascularisation, but there is conflicting 
evidence for this recommendation. Only two small randomised 
trials and two post-hoc subgroup analyses of larger randomised 
trials have evaluated invasive versus non-invasive management 
for NSTEMI in older patients: a meta-analysis that pooled data 
from these trials did not find clear evidence that invasive therapy 
reduced long-term mortality (odds ratio 0·84, 95% CI 0·66–1·06).
Although registry studies have attempted to address whether 
the benefit of invasive management extends to older  patients, 
their results might have been affected by immortal time bias, 
because patients who died early in the course of their 
presentation, before invasive therapy could be considered or 
arranged, were assigned to the non-invasive group.
Added value of this study
To our knowledge this is the first study to estimate the effect of 
invasive compared with non-invasive management of NSTEMI 
on the survival of patients aged 80 years or older using 
multicentre, routine clinical data and methods that help to 
minimise bias in analyses of observational data by considering 
the target trial that would answer the clinical question. This study 
provides evidence that the survival advantage from invasive 
management might extend to patients aged 80 years or older 
with NSTEMI (adjusted hazard ratio 0·68, 95% CI 0·55–0·84).
Implications of all the available evidence
This study strengthens the evidence for an invasive approach to 
management of patients aged 80 years or older with NSTEMI. 
Ideally, clinical decision making should be driven by findings 
from randomised trials. In the absence of randomised trial data, 
clinical decisions need to be made on the basis of the best 
available evidence. An invasive approach might be the better 
management strategy in patients who could be managed 
either invasively or non-invasively.
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Hospital, London) in the UK, which were all tertiary 
centres with emergency departments.
We defined the target trial as comparing patients 
who had invasive management for NSTEMI (defined 
as coronary angiography with or without subsequent 
revascularisation within 3 days of peak troponin concen-
tration) with patients who did not receive such invasive 
management. We followed all included patients from the 
time of their peak troponin concentration until death or 
censoring in April, 2017.
Eligible patients were 80 years old or older when they 
underwent troponin measurements and were diagnosed 
with NSTEMI between 2010 (2008 for University College 
Hospital) and 2017. Only the first episode of hospital care 
with troponin measure ments was eligible. Classification 
of NSTEMI was made on the basis of the assigned 
International Statistical Classification of Diseases and 
Related Health Problems discharge codes (I21.4; acute 
subendocardial myocardial infarction).17 Patients with a 
concurrent primary diagnosis of an acute illness associated 
with possible oxygen supply-and-demand mismatch were 
excluded.
We used the target trial to minimise bias by starting 
follow up at the time of peak troponin; ensuring that early 
deaths did not influence the definition of the intervention 
group, to avoid immortal time bias; excluding patients 
Figure 1: Study profile
ACS=acute coronary syndrome. NSTEMI=non-ST elevation myocardial infarction. Invasive management defined as angiography with or without revascularisation within 
3 days of peak troponin concentration. *57 of the 77 deaths in patients not invasively managed within 3 days of the peak troponin concentration had eligible propensity 
scores and were assigned to treatment groups using multiple imputation. Across the imputed datasets, on average, ten were included in the invasive management group 
and 47 were included in the non-invasive management group.






1976 had a primary diagnosis of NSTEMI
116 had missing data
696 had concurrent acute primary illness
816 had STEMI
713 had unstable angina
 57 025 had non-ACS disease
860 had invasive management 
within 3 days of the peak 
troponin concentration
24 died within 3 days
836 survived 3 days after the peak 
troponin concentration
655 had eligible propensity scores 21 had eligible propensity scores
686 included in invasive management group for intention-to-treat analysis at 3-year follow-up
77 died within 3 days
892 included in non-invasive management group for 
intention-to-treat analysis at 3-year follow-up
1116 did not have invasive 
management within 3 days 
of the peak troponin 
concentration
1039 survived 3 days after the 
peak troponin concentration
181 had extreme 
propensity scores 
3 had extreme 
propensity scores 
20 had extreme 
propensity scores 
194 had extreme 
propensity scores 
845 had eligible propensity scores
10 on average assigned to invasive 
group by multiple imputation
57 had eligible propensity scores*
47 on average assigned to
non-invasive group by multiple 
imputation
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with a high probability of being assigned to one of the 
treatment groups (patients included in a trial must be 
eligible to receive each treatment); using regression 
models that included the propensity score to control 
confounding; and doing intention-to-treat analyses, in 
which patients who received invasive intervention after 
the first three days were analysed in the non-invasive 
management group. This study was approved by 
the London-South East Research Ethics Committee 
(REC reference: 16/HRA/3327).
Outcomes
The primary outcome was all-cause mortality. The 
secondary outcome was the number of hospital admis-
sions for heart failure during follow-up. In post-hoc 
analyses we examined new hospital admissions for 
bleeding, stroke, acute coronary syndrome, and further 
invasive management. Bleeding was defined as minor or 
major bleeding. Vital status was ascertained using 
the national Patient Demographic Service, which 
incorporates national death registry information and 
local notifications. We could only ascertain heart failure 
admission using electronic health record data in the 
hospital where their initial NSTEMI diagnosis was 
made.
Statistical analysis
In a randomised trial, follow-up starts at the time that 
treatment strategies are assigned. In the absence of such 
assignment, follow-up in patients who do not undergo 
invasive management is consistent with both treatment 
strategies for the first 3 days. Classification of patients 
who die within 3 days of peak troponin concentration 
without invasive management to the comparison group 
can cause an immortal time bias because some patients 
could have had invasive management had they not 
died.10,11 To limit such bias, patients who died within 
3 days of peak troponin concentration were excluded 
from the initial modelling steps, then included separately.
Propensity scores (patients’ estimated probability of 
receiving invasive management) were derived using 
logistic regression, for patients who did not die within 
3 days of peak troponin concentration. The final propen-
sity score model was based on backwards stepwise 
selection, with a p value threshold of 0·2. We considered 
the following pretreatment variable groups: patient 
demographics, blood test results, cardiovascular risk 
factors, cardiovascular disease, renal disease, respiratory 
disease, neurological disease, psychiatric disease, other 
comorbidities, and markers of frailty. The Comorbidity 
Domain of the Frailty Index was calculated as a score 
ranging between 0 and 1.18 All the variables considered 
and those selected into the propensity score model are 
listed in the appendix (pp 9–10). Non-linear relationships 
were modelled using smoothing splines. Analyses used 
the first mea surement of each haematological and 
biochemical blood test during the hospital care episode, 
except for troponin concentration for which the peak 
measurement was used.
We examined the number of patients and deaths in each 
treatment group, within strata defined by propensity score 
quantiles. Participants in a randomised trial must be 
eligible to receive any of the interventions being compared. 
Therefore, patients in a stratum for which there were few 
patients or deaths in either group were excluded, to make 
it more likely that analyses were restricted to patients 
eligible to receive either treatment strategy. In such 
patients, inverse probability of treatment weights were 
defined as 1/propensity score in patients who received 
invasive management and as 1/(1–pro pensity score) in 
patients who received non-invasive management.
We used Kaplan-Meier plots to display the cumulative 
risk of mortality and hospital admission for heart failure 
over time in each treatment group. The plots were 
weighted for inverse probability of treatment to estimate 
Figure 2: Combined histogram and probability density function of the propensity score for 1875 patients 
with non-ST elevation myocardial infarction in patients aged 80 years or older according to invasive or 
non-invasive management strategy
Invasive management defined as angiography with or without revascularisation within 3 days of peak troponin 
concentration. Patients with propensity scores <10% had a high probability of receiving non-invasive treatment 
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the cumulative risk had all eligible patients been assigned 
to one or the other group.
We used Cox models (stratified by centre) to estimate 
mortality hazard ratios (HR) comparing invasive man-
agement with non-invasive management in patients 
who did not die within 3 days of their peak troponin 
concentra tion and who were in the eligible propensity 
score strata. Two approaches were used to control 
confounding: multi variable adjustment (including the 
propensity score modelled using a restricted cubic 
spline) and inverse probability of treatment weighting. 
The variables adjusted for were chosen using backwards 
stepwise selection, with a p value threshold of 0·2, and 
treatment group was included in all models. The same 
variables were considered for inclusion in the Cox 
models as for the propensity score model (appendix 
pp 9–10). We then included patients in eligible 
propensity score strata who died within 3 days of their 
peak troponin concentration. Those who had received 
invasive inter vention were classified in the invasive 
management group: the others (who might have 
received invasive intervention had they not died) were 
randomly assigned to the invasive or non-invasive 
management group on the basis of their propensity 
scores. We generated 20 datasets, estimated mortality 
HRs in each, then pooled the results using Rubin’s 
rules to estimate the overall HR. The pretreatment 
variables included in these Cox model analyses are 
listed in the appendix (pp 9–10).
In sensitivity analyses, we quantified the potential for 
unmeasured confounding to explain the effect of invasive 
management on estimated mortality hazard ratios by 
calculating the E value.19 We investigated the effect of 
assigning all patients who died within 3 days of their 
peak troponin concentration to one or the other treatment 
group and of reducing the number of eligible propensity 
score strata. Changes in the HR with age were investi-
gated using cubic splines. The number of hospital 
admissions relating to heart failure in the invasive 
management and non-invasive management groups 
were compared using negative binomial regression 
adjusted by centre. The pretreatment variables included 
were selected using backwards stepwise selection, with 
a p value threshold of 0·2, and are listed in the appendix 
(pp 9–10).
Statistical analyses used R (version 3.5.0) and Stata 
(version 16.0). The data acquisition plan is in the appendix 
(pp 19–23). The study is registered with ClinicalTrials.gov, 
NCT03507309.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing the report. 
AK, JACS, and AT had access to all data and take full 
responsibility for its integrity and the accuracy of the 
analyses. The corresponding author had final respon-
sibility for the decision to submit for publication.
Results
Of the 61 342 patients aged 80 years or older who 
had troponin measured in the study period Jan, 2010 
(Jan, 2008 for University College Hospital, London, UK) 
to April, 2017, 2788 (4·5%) had a diagnosis of NSTEMI. 
116 (4·2%) patients were excluded because of missing 
data in one or more variables and 696 (25%) had a con-
current primary diag nosis with an acute illness (appendix 
p 11).
Of the 1976 patients included, 961 (49%) underwent 
invasive management during their index admission of 
whom 860 (89%) had invasive management during the 
first 3 days after peak troponin concentration (appendix 
p 3). There were 890 (45%) deaths in the 1976 patients 
included, of which 101 were within the first 3 days after 
peak troponin concentration. These 101 patients were 
excluded from the next stage of the analyses (figure 1). 
The characteristics of these patients are shown in the 
appendix (pp 12–13).
Characteristics of the patients that were associated 
with receiving invasive man agement are shown in 
the appendix (pp 4–5, 14–15). The propensity score 
distributions for patients treated invasively and non-
invasively are shown in figure 2. The proportion of 
patients who died during follow-up in each group, 
according to propensity score quantiles, are shown in 
table 1. In both treatment groups, the proportion who 
died was higher in patients with lower propensity scores 
(those most likely to be non-invasively managed). Below 
the tenth percentile (propensity score=0·0178) none of 
the 188 patients were invasively managed and above the 
90th percentile (propensity score=0·9292) only six (3%) 
of 187 patients were non-invasively managed. Therefore, 



















99 to 100 1·0000 19 3 (16%) 0 0 ··
95 to <99 0·9936 73 20 (27%) 2 0 ··
90 to <95 0·9633 89 23 (26%) 4 0 ··
75 to <90 0·9292 232 53 (23%) 49 14 (29%) 0·64 (0·34–1·18)
50 to <75 0·7742 294 85 (29%) 176 69 (39%) 0·61 (0·44–0·85)
25 to <50 0·4154 117 41 (35%) 352 177 (50%) 0·49 (0·35–0·69)
10 to <25 0·0987 12 6 (50%) 268 168 (63%) 0·72 (0·32–1·63)
5 to <10 0·0178 0 0 95 62 (65%) ··
1 to <5 0·0054 0 0 74 52 (70%) ··
0 to <1 0·0007 0 0 19 16 (84%) ··
Overall ·· 836 231 (28%) 1039 558 (54%) 0·34 (0·29–0·40)
Invasive management defined as an invasive procedure within 3 days of peak troponin concentration.
Table 1: Proportion of deaths in the invasive management and non-invasive management groups, 
according to percentiles of the propensity score for the study population who survived up to 3 days from 
peak troponin concentration
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Age (years) 85·3 (4·3) 86·9 (4·9) 1·6 (1·2 to 2·1) ··
Haematology and biochemistry results
C-reactive protein (mg/L) 25·2 (45·2) 35·8 (56·2) 10·6 (5·4 to 15·9) ··
Creatinine (µmol/L) 113·7 (85·9) 121·5 (94·9) 7·8 (–1·5 to 17·1) ··
Haemoglobin (g/dL) 12·5  (1·9) 12·1 (1·9) –0·3 (–0·5 to –0·2) ··
Platelet count (10⁹ cells per L) 229·1 (74·9) 236·3 (82·7) 7·1 (–1·0 to 15·2) ··
Potassium (mmol/L) 4·3 (0·6) 4·3 (0·6) 0·1 (–0·0 to 0·1) ··
Sodium (mmol/L) 136·9 (4·2) 137·1 (4·9) 0·2 (–0·2 to 0·7) ··
Troponin (upper limit of normal) 270·2 (510·4) 177·6 (375·7) –93 (–137 to –48) ··
White cell count (10⁹ cells per L) 9·6 (3·5) 10·1 (4·0) 0·5 (0·1 to 0·9) ··
Frailty
Comorbidity domain of Frailty Index score 0·22 (0·09) 0·23 (0·09) 0·01 (0·00 to 0·02) ··
Binary characteristics
Demographic characteristics
Interhospital transfer 73 (11%) 32 (4%) ·· 3·19 (2·08 to 4·89)
Male sex 390 (60%) 418 (50%) ·· 1·50 (1·22 to 1·85)
Cardiovascular risk factors
Diabetes 172 (26%) 201 (24%) ·· 1·14 (0·90 to 1·44)
Family history of ischaemic heart disease 108 (16%) 55 (7%) ·· 2·84 (2·01 to 3·99)
Hypercholesterolaemia 275 (42%) 253 (30%) ·· 1·69 (1·37 to 2·10)
Hypertension 406 (62%) 456 (54%) ·· 1·39 (1·13 to 1·71)
Tobacco use 237 (36%) 152 (18%) ·· 2·59 (2·04 to 3·28)
Cardiovascular disease
Abdominal aortic aneurysm 3 (1%) 7 (1%) ·· 0·55 (0·14 to 2·14)
Angina 132 (20%) 160 (19%) ·· 1·08 (0·84 to 1·40)
Aortic stenosis 34 (5%) 57 (7%) ·· 0·76 (0·49 to 1·17)
Atrial fibrillation 105 (16%) 155 (18%) ·· 0·85 (0·65 to 1·12)
Cardiogenic shock 6 (1%) 7 (1%) ·· 1·11 (0·37 to 3·31)
Cardiac arrest 10 (2%) 13 (2%) ·· 0·99 (0·43 to 2·28)
Complete heart block 9 (1%) 14 (2%) ·· 0·83 (0·36 to 1·92)
Heart failure 110 (17%) 205 (24%) ·· 0·63 (0·49 to 0·82)
Peripheral vascular disease 40 (6%) 46 (5%) ·· 1·13 (0·73 to 1·75)
Previous myocardial infarction 498 (76%) 475 (56%) ·· 2·47 (1·97 to 3·09)
Supraventricular tachycardia 1 (0·2%) 3 (0·4%) ·· 0·43 (0·04 to 4·14)
Ventricular fibrillation 5 (0·8%) 7 (1%) ·· 0·92 (0·29 to 2·91)
Ventricular tachycardia 9 (1%) 8 (1%) ·· 1·46 (0·56 to 3·80)
Renal disease
Acute renal failure 33 (5%) 74 (9%) ·· 0·55 (0·36 to 0·84)
Chronic kidney disease (>stage 2) 48 (7%) 70 (8%) ·· 0·88 (0·60 to 1·28)
Urinary tract infection 17 (3%) 60 (7%) ·· 0·35 (0·20 to 0·60)
Respiratory disease
Interstitial lung disease 5 (0·8%) 28 (3%) ·· 0·22 (0·09 to 0·58)
Obstructive lung disease 84 (13%) 117 (14%) ·· 0·92 (0·68 to 1·24)
Other lung disease 65 (10%) 116 (14%) ·· 0·69 (0·50 to 0·96)
Pneumonia 35 (5%) 78 (9%) ·· 0·56 (0·37 to 0·84)
Pulmonary embolism 3 (0·5%) 2 (0·2%) ·· 1·94 (0·32 to 11·6)
Respiratory failure 9 (1%) 25 (3%) ·· 0·46 (0·21 to 0·99)
(Table 2 continues on next page)
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scores were between the tenth and 90th percentiles 
(figure 1). The characteristics of patients very likely 
to receive non-invasive interventions (<10th percentile) 
and those very likely to receive invasive management 
(>90th percentile) are shown in the appendix (pp 12–13).
The 1500 patients included in the next stage of analyses 
had a median age of 86 (IQR 82–89) years (table 2; 
appendix pp 12–13). Revas cularisation was done in 
486 (74%) of 655 patients undergoing invasive manage-
ment. The strongest predictors of invasive management 
were interhospital transfer (odds ratio [OR] 3·19, 95% CI 
2·08–4·89) and family history of ischaemic heart disease 
(2·84, 2·01–3·99), whereas interstitial lung disease 
(0·22, 0·09–0·58) and indicators of frailty were strong 
predictors of non-invasive management (table 2).
During median 3·0 (IQR 1·2–4·8) years follow-up 
there were 613 (41%) deaths. At 5 years, Kaplan-Meier 
estimates of cumulative mortality from 3 days after peak 
troponin concentration were 31% (168 events) in the 
invasive management group and 61% (413 events) in the 
non-invasive group (appendix p 6). Inverse probability 









(Continued from previous page)
Neurological disease
Ischaemic stroke 6 (0·9%) 17 (2%) ·· 0·45 (0·18 to 1·15)
Parkinson’s disease 5 (0·8%) 7 (1%) ·· 0·92 (0·29 to 2·91)
Subdural haemorrhage 2 (0·3%) 1 (0·1%) ·· 2·58 (0·23 to 28·6)
Psychiatric disease
Alcohol misuse 20 (3%) 44 (5%) ·· 0·57 (0·33 to 0·98)
Anxiety 4 (0·6%) 15 (2%) ·· 0·34 (0·11 to 1·03)
Bipolar disease 1 (0·2%) 4 (0·4%) ·· 0·32 (0·04 to 2·88)
Delirium 3 (0·5%) 15 (2%) ·· 0·25 (0·07 to 0·88)
Depression 9 (1%) 18 (2%) ·· 0·64 (0·29 to 1·43)
Other psychiatric illness 59 (9%) 91 (11%) ·· 0·82 (0·58 to 1·16)
Other comorbidities
Arthritis 13 (2%) 37 (4%) ·· 0·44 (0·23 to 0·84)
Constipation 14 (2%) 23 (3%) ·· 0·78 (0·40 to 1·53)
Fracture 5 (0·8%) 12 (1%) ·· 0·53 (0·19 to 1·52)
Gastric ulcer 2 (0·3%) 4 (0·4%) ·· 0·64 (0·12 to 3·53)
Haemorrhage 25 (4%) 29 (3%) ·· 1·12 (0·65 to 1·93)
Inflammatory disorder 57 (9%) 114 (13%) ·· 0·61 (0·44 to 0·86)
Malignancy 43 (7%) 81 (10%) ·· 0·66 (0·45 to 0·97)
Metabolic disorder 5 (0·8%) 23 (3%) ·· 0·27 (0·10 to 0·73)
Sepsis 6 (0·9%) 22 (3%) ·· 0·35 (0·14 to 0·86)
Frailty
Bowel incontinence 11 (2%) 36 (4%) ·· 0·38 (0·19 to 0·76)
Dementia 9 (1%) 41 (5%) ·· 0·27 (0·13 to 0·57)
History of falls 16 (2%) 63 (7%) ·· 0·31 (0·18 to 0·54)
Impaired hearing 6 (0·9%) 22 (3%) ·· 0·35 (0·14 to 0·86)
Impaired vision 3 (0·5%) 15 (2%) ·· 0·25 (0·07 to 0·88)
Mild cognitive impairment (no dementia) 5 (0·8%) 19 (2%) ·· 0·33 (0·12 to 0·90)
Need for assistance at home 57 (9%) 113 (13%) ·· 0·62 (0·44 to 0·86)
Need for mobility assistance 41 (6%) 84 (10%) ·· 0·60 (0·41 to 0·89)
Need for personal care assistance 6 (0·9%) 22 (3%) ·· 0·35 (0·14 to 0·86)
Reduced mobility 9 (1%) 26 (3%) ·· 0·44 (0·20 to 0·94)
Speaking difficulty 6 (0·9%) 22 (3%) ·· 0·35 (0·14 to 0·86)
Urinary catheterisation 5 (0·8%) 11 (1%) ·· 0·58 (0·20 to 1·69)
Urinary incontinence 14 (2%) 18 (2%) ·· 1·00 (0·50 to 2·03)
Weight loss 7 (1%) 23 (3%) ·· 0·39 (0·16 to 0·91)
All data are mean (SD) for numerical characteristics or n (%) for binary characteristics. Only participants who survived for 3 days after peak troponin concentration were 
included. Comparisons between groups are unadjusted and are quantified as mean differences for numerical characteristics and odds ratios for binary characteristics.
Table 2: Characteristics of participants who survived for at least 3 days after peak troponin concentration according to invasive or non-invasive 
management strategy
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estimated 5-year cumulative mortality of 36% if all these 
patients received invasive intervention, compared with 
55% if all received non-invasive intervention (figure 3A).
The crude mortality HR comparing invasive with non-
invasive management from 3 days after peak troponin 
concentration was 0·38 (95% CI 0·32–0·46), attenuated 
to 0·56 (0·45–0·70) after multivariable adjustment 
for clinical characteristics and propensity score. The 
mortal ity HR was further attenuated (0·66, 0·49–0·88] 
following inverse probability of treatment weighting 
(table 3).
The propensity score distributions for the 101 patients 
who died within 3 days of their peak troponin concen-
tration are shown in the appendix (p 7). 77 (76%) patients 
received non-invasive management and 78 patients had 
a propensity score between the 10th and 89th percen-
tiles. When these patients were assigned to treatment 
groups based on their propensity score using multiple 
imputation (primary analysis), the mortality HR was 
0·68 (95% CI 0·55–0·84). The E value for unmeasured 
confounding was 1·94. The adjusted HRs were 1·05 
(0·86–1·27) after assigning all patients who died within 
3 days of their peak troponin concentration to the 
invasive group and 0·50 (0·40–0·61) after assigning 
them to the non-invasive group (table 3).
Including patients whose propensity score were 
between the 25th and 75th percentiles (figure 2) led to an 
adjusted HR of 0·56 (95% CI 0·44–0·71) from 3 days 
after peak troponin concentration. There was no evi-
dence of an association between invasive manage ment 
and lower mortality during the first month of follow-up, 
although the strongest associations of invasive manage-
ment with lower mortality were from 1 year of follow-up 
onwards (appendix p 16). The association of invasive 
management with lower mortality appeared to attenuate 
with increasing age, but smaller patient numbers at the 
oldest ages meant that the confidence intervals on age-
specific HRs were wide (appendix p 8).
The numbers of patients who were invasively managed 
during follow-up were 103 (16%) of 655 in the invasive 
management group and 161 (19%) of 845 in the non-
invasive group (appendix p 17). 120 (14%) of 845 patients 
in the non-invasive group were invasively managed 
between 4 and 28 days after their peak troponin. However, 
the proportion of patients who were invasively managed 
after 28 days was smaller for the non-invasive group than 
in the invasive group. Invasive management was done 
during a recurrent acute coronary syndrome admission 
in only 43 (5%) patients in the invasive group and 
71 (8%) patients in the non-invasive group. Of those 
undergoing further invasive manage ment in the invasive 
group, 68 (66%) had revas cularisation, compared with 
24 (15%) of those in the non-invasive management group 
during their index hospital admission.
The number of patients admitted with heart failure 
during follow up was 76 (mean 0·20 admissions; 
range 0–7) in the invasive group and 127 (mean 
0·24 admissions; range 0–6) in the non-invasive group. 
At 5 years, the cumulative percentages admitted to 
hospital with heart failure were 15% in the invasive group 
and 22% in the non-invasive group (appendix p 6). An 
inverse probability of treatment weighted Kaplan-Meier 
plot estimated 5-year cumulative admission rates to be 
14% if all eligible patients were invasively managed and 
19% if all eligible patients were non-inva sively managed 
(figure 3B). Invasive management was associated with a 
lower incidence of hospital admissions for heart failure 
than non-invasive management (adjusted incidence rate 
Figure 3: Kaplan-Meier curves displaying cumulative all-cause mortality and probability of admission for 
heart failure according to invasive and non-invasive management
(A) Cumulative all-cause mortality. (B) Probability of admission for heart failure. Plots are weighted according to 
the inverse probability of treatment received. They compare outcomes if all eligible patients were invasively or 
non-invasively managed. Patient deaths within 3 days of peak troponin were excluded. Hazard ratios are inverse 








































































































HR 0·66 (95% CI 0·49–0·88); p=0·0050
HR 0·63 (95% CI 0·44–0·91); p=0·013 
Articles
www.thelancet.com   Vol 396   August 29, 2020 631
ratio 0·67, 95% CI 0·48–0·93; appendix p 18). Association 
between invasive management and additional causes 
of hospital admission are reported in the appendix 
(pp 2, 18).
Discussion
We used multicentre routine clinical data from the 
NIHR Health Informatics Collaborative to estimate the 
effect of invasive management compared with non-
invasive management on survival and other outcomes in 
patients with NSTEMI aged 80 years or older. We used a 
frame work for comparative effectiveness research based 
on explicit description of the target trial whose results 
would answer the clinical question.14 The estimated 
32% lower mortality in patients who receive invasive 
management compared with those who receive non-
invasive manage ment strengthens the evidence for an 
invasive approach. Invasive management was associated 
with a lower incidence of heart failure hospitalisations, 
acute coronary syndrome, and invasive management 
during follow-up.
Patients aged 80 years or older represent a growing 
proportion of the population presenting with NSTEMI, 
but these patients are much less likely to receive invasive 
management. Data from the National Inpatient Sample 
database in the USA showed that coronary angiography 
was done in 78% of patients with NSTEMI aged 60 years 
or younger, compared with 38% of patients aged 
81 years or older.5 In our study, 49% of eligible patients 
underwent invasive management during their index 
admission. These differences do not necessarily reflect 
ageism, rather they reflect insufficient data to guide 
clinical practice. Treatment decisions are often made in 
the context of careful evaluation of potential risks and 
benefits, estimated life expectancy, and comorbidities. 
In our study, patients managed non-invasively had 
worse prognosis and were more likely to have a history 
of heart failure, chronic kidney disease, malignancy, 
and lung disease. Patients managed invasively were 
more likely to have higher troponin concentrations, 
blood test results within the normal range, and 
cardiovascular risk factors (including smoking, family 
history of ischaemic heart disease, hypertension, and 
hypercholesterolaemia). Such risk factors are generally 
associated with better prognosis in patients who have 
had an index event, such as myocardial infarction.20,21
The European Society of Cardiology guidelines suggest 
that older patients should be considered for invasive 
management and revascularisation (class 2a recom men-
dation: “conflicting evidence and/or a divergence of opinion 
about the usefulness/efficacy of the given treatment or 
procedure” but the “weight of evidence/opinion is in favour 
of usesfulness/efficacy”.22 The American Heart Association 
have a similar guideline recommendation.23 Only two small 
randomised trials (After Eighty24 [invasive group n=229 and 
non-invasive group n=228] and Italian Elderly ACS Trial25 
[invasive group n=154 and non-invasive group n=159]) and 
two small post-hoc subgroup analyses of randomised 
trials (TACTICS-TIMI 1826 and FIR27) have evaluated inva-
sive management versus non-invasive management for 
NSTEMI in patients aged 75–80 years or older. A meta-
analysis that pooled these data, published in 2017, did not 
find clear evidence that invasive management reduced 
long-term mortality (OR 0·84, 95% CI 0·66–1·06; p=0·15).28 
Number in the 
invasive group






Multivariable* plus PS adjustment, with deaths within 3 days of peak troponin 
concentration assigned to a treatment group based on PS†
686 892 0·68 (0·55–0·84) <0·0001
Sensitivity analyses
Crude, excluding deaths within 3 days of peak troponin concentration 655 845 0·38 (0·32–0·46) <0·0001
Multivariable* plus PS adjustment, excluding deaths within 3 days 655 845 0·56 (0·45–0·70) <0·0001
IPTW, excluding deaths within 3 days 655 845 0·66 (0·49–0·88) 0·0050
Multivariable* plus PS adjustment, restricted to patients with PS in the 25th and 
75th percentiles, excluding deaths within 3 days
411 528 0·56 (0·44–0·71) <0·0001
Multivariable* plus PS adjustment, with deaths within 3 days of peak troponin 
concentration assigned to the non-invasive group
655 923 0·50 (0·40–0·61) <0·0001
Multivariable* plus PS adjustment, with deaths within 3 days of peak troponin 
concentration assigned to the invasive group
733 845 1·05 (0·86–1·27) 0·65
IPTW=inverse probability of treatment weighted. PS=propensity score. *Adjusted for age, interhospital transfer, creatinine and haemoglobin concentration, family history of 
ischaemic heart disease, hypercholesterolaemia, hypertension, abdominal aortic aneurysm, angina, aortic stenosis, cardiogenic shock, heart failure, previous myocardial 
infarction, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia, acute renal failure, urinary tract infection, interstitial lung disease, obstructive lung 
disease, other lung disease, ischaemic stroke, Parkinson’s disease, anxiety, gastric ulcer, metabolic disorder, bowel incontinence, dementia, history of falls, mild cognitive 
impairment (no dementia), need for mobility assistance, and speaking difficulty. †57 of the 77 deaths in patients not invasively managed within 3 days of the peak troponin 
concentration had eligible propensity scores and were assigned to treatment groups using multiple imputation. Across the imputed datasets, on average, ten were included in 
the invasive management group and 47 were included in the non-invasive management group.
Table 3: Estimated mortality hazard ratios comparing invasive with non-invasive management, for patients with non-ST elevation myocardial infarction 
aged 80 years or older
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hospitals which directly admit older patients with 
NSTEMI.
The main limitations of our study relate to its 
observational nature: we cannot exclude bias due to 
uncontrolled (residual) confounding. However, we took 
several steps to minimise bias, using specification of a 
target trial to guide our analyses. We assigned patients 
who died within 3 days of their peak troponin concen-
tration to the two treatment groups according to their 
propensity scores, unless they had been invasively 
managed before death. 3 days was chosen as the optimal 
time to capture most of the patients who underwent 
invasive management in our cohort (appendix p 3) and 
the median time used in previous randomised trials.24,25 
Patients who received invasive management after 3 days 
were analysed in the non-invasive group, as would be the 
case in an intention-to-treat analysis of a randomised 
trial.
Confounding by indication is a major concern for 
interpretation of our results: patients with worse prog-
nosis were markedly more likely to receive non-invasive 
management. We considered more than 70 potentially 
confounding variables, including patient demographics, 
comorbidities, and cardiovascular risk factors. We 
excluded patients in the propensity score strata in which 
there were few patients or deaths in either group and 
controlled for potential confounding by a large range of 
prognostic factors. However, our results could be biased 
by unmeasured confounding, by factors such as frailty 
that might not be well captured in routinely collected 
data. We did not have information on whether there was 
differential receipt of evidence-based cardiac care in the 
non-invasive management group, including prescrip-
tion of medications. Additionally, we did not have data 
on postadmission prognostic factors that might have 
affected choice of invasive or non-invasive management 
within the first 3 days. Calculation of the E value 
showed that to explain the effect of invasive management 
on mortality estimated in our study, an unmeasured 
confounder would need at minimum to have a risk ratio 
of 1·94 with both undergoing invasive management 
and mortality, having controlled for all the measured 
confounders.19
Our study strengthens the evidence for an invasive 
approach to management of older patients with NSTEMI. 
Ideally, clinical decision making should be driven by 
randomised trials. However, the only ongoing trial 
designed to answer this question is not due for com-
pletion until the end of the current decade.13 In the 
meantime, clinical decisions need to be made based on 
the best available evidence, which suggests that an 
invasive approach might be the better strategy for older 
patients who could be managed either invasively or non-
invasively. Further research into the threshold (based on 
prognostic factors and comorbidities) at which invasive 
management should be considered would further assist 
clinical decision making.
Inter pretation is difficult because TACTICS-TIMI 18 com-
pared an early invasive with a selective invasive strategy 
with predischarge ischaemia test, following which 49% of 
patients underwent coronary catheterisation and 32% had 
revascularisation.26 Similarly, the FIR trials, which reported 
cardiovascular mortality but not all-cause mortality, com-
pared an invasive strategy with a selective invasive strategy, 
which involved a predischarge ischae mia test, following 
which nearly half of patients had revas cularisation 
during follow-up.27 In the Italian Elderly ACS Study, 
29% of patients randomly assigned to receive non-invasive 
management had coronary catheter isation.25 In our study, 
161 (19%) of 845 patients analysed in the non-invasive 
group underwent invasive manage ment during follow-up, 
of whom only 24 (15%) were revascularised. There were 
inconsistencies between the four trials with regard to the 
timing of angiography after randomisation, ranging from 
4 h to 7 days, and the duration of patient follow-up following 
randomisation, ranging from 6 months to 5 years.24–27
The ongoing SENIOR-RITA trial13 aims to randomly 
assign 2300 patients with NSTEMI aged 75 years or older 
to receive invasive or non-invasive management. With 
a 5-year follow-up planned, the primary outcome is a 
composite of cardiovascular death and non-fatal myocar-
dial infarction, with an estimated study completion 
in 2029.13
In the absence of compelling evidence from ran-
domised trials, a small number of registry studies7–9 have 
suggested a benefit from invasive therapy, but the 
findings might have been exaggerated by immortal time 
bias and the inclusion of very frail patients who were 
almost certain to be managed non-invasively. Immortal 
time bias can occur when patients who would have 
received active intervention are analysed in the no 
intervention or conservative intervention group because 
they died before active intervention was implemented.10,11 
Studies of temporal trends using registry data from 
the USA and Europe suggest that over the past 15 years 
the progressive switch from a non-invasive to more 
invasive approach in older patients with NSTEMI has 
been accompanied by declining mortality.5,29,30
We analysed a large, detailed clinical dataset assembled 
from routinely collected data on unselected patients. 
All-cause mortality is the outcome of most interest to 
patients. However, we could not identify deaths that 
were related to cardiac pathology. In older patients, 
deaths from causes, such as cancer, that are not affected 
by management of NSTEMI are common. This suggests 
that any effect of invasive management on cardiovascular 
mortality is likely to be greater than its effect on all-cause 
mortality. We were unable to explore some outcomes of 
interest (eg, independent living and quality of life). The 
five centres contributing data were all tertiary centres 
with most patients being admitted directly. Only 
105 (7%) of 1500 patients of the cohort were transferred 
from other hospitals to these centres. Therefore, we 
believe that the findings are generalisable to other 
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On the basis of routinely collected clinical data from 
five UK tertiary centres we found that invasive manage-
ment in patients aged 80 years or older with NSTEMI was 
associated with 32% lower mortality, compared with non-
invasive management. The survival advantage bestowed 
by invasive management might extend to patients aged 
80 years or older with NSTEMI.
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